A5047910320- Lung Cancer Treatments and Mutations
- Photochromic and Fluorescence Chemistry
- Extraction and Separation Processes
- Electrospun Nanofibers in Biomedical Applications
- Porphyrin and Phthalocyanine Chemistry
- Molecular Sensors and Ion Detection
- Biosimilars and Bioanalytical Methods
- Minerals Flotation and Separation Techniques
- Cancer Immunotherapy and Biomarkers
- Photoreceptor and optogenetics research
- Metal Extraction and Bioleaching
- Lung Cancer Research Studies
- Advanced Battery Materials and Technologies
- Free Radicals and Antioxidants
- Cancer Genomics and Diagnostics
- Mobile Health and mHealth Applications
- Enzyme function and inhibition
- Antimicrobial agents and applications
- Graphene and Nanomaterials Applications
- Advanced Cellulose Research Studies
- Economic and Financial Impacts of Cancer
- Click Chemistry and Applications
- Metal Alloys Wear and Properties
- Telemedicine and Telehealth Implementation
- Polymer Nanocomposite Synthesis and Irradiation
Union Hospital
2023-2025
Huazhong University of Science and Technology
2023-2025
Wuhan Union Hospital
2024-2025
Chinese Academy of Sciences
2024
University of Chinese Academy of Sciences
2024
Shanghai Institute of Ceramics
2024
Henan Provincial People's Hospital
2024
Sichuan Agricultural University
2020-2021
Guangdong Institute of New Materials
2020-2021
Guangdong Academy of Sciences
2021
Abstract Sodium is an abundant resource standing as one of the most promising alternatives to lithium for next generation battery anode materials. Solid polymer electrolytes (SPEs) present a prospective choice realizing sodium‐metal batteries. SPEs exhibit excellent interface compatibility, but crucial bottleneck how achieve high ionic conductivity and Na + transference number simultaneously. Herein, using one‐step ion exchange method synthesize 2‐Acrylamido‐2‐methylpropanesulfonic acid...
Abstract HA121-28, a promising multikinase inhibitor, mainly targets rearranged during transfection (RET) fusions and selectively vascular endothelial growth factor receptor-2, receptor, fibroblast receptor 1-3. The safety, pharmacokinetics, efficacy of HA121-28 were assessed in advanced solid tumors (phase 1, ClinicalTrials.gov NCT03994484) RET fusion-positive non-small-cell lung cancer (RET-TKI naive NSCLC, phase 2, NCT05117658). was administered orally doses range from 25 to 800 mg under...
Abstract Background: Resistance mechanisms to first-generation (1G) KRAS G12C inhibitors (G12Ci) are diverse, with previous data revealing a heterogeneous pattern characterized by multiple subclonal events emerging after treatment (Tx). Incomplete target engagement (TE) and G12Ci induced amplification contributed the resistance against 1G G12Ci. D3S-001, next-generation G12Ci, has demonstrated potent, faster complete TE effectively deplete active mutated protein. In pre-clinical studies,...
After the global approval of atezolizumab plus bevacizumab and chemotherapy as first-line metastatic nonsquamous non-small-cell lung cancer (nsqNSCLC) treatment, IMpower151 ( NCT04194203 ) trial was conducted in China to address regional differences. Chemotherapy-naive patients with nsqNSCLC (N = 305) were randomized 1:1 receive either atezolizumab, bevacizumab, carboplatin paclitaxel or pemetrexed (ABCPem/Pac; n 152) placebo (BCPem/Pac; 153). The primary endpoint investigator-assessed...
e15002 Background: Hemay181 is a broad-spectrum anti-tumor cytotoxic drug with tumor-targeting properties (about 44808 ASCO24). The prodrug conjugate enzymatically cleaved by beta-glucuronidase (β-GU) in tumor tissues, selectivity associated increased expression of β-GU the microenvironment. On enzymatic cleavage, SN-38 released. In animal Xenograft models, tumor-to-plasma ratio 75 fold for Hemay181, 12x Govitecan, 0.3 Irinotecan showing concentration. Methods: An ascending dose exploration...
3041 Background: Treatment options are limited for patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) that progress after platinum-based chemotherapy (chemo). ZL-1310, a DLL3-targeted antibody drug conjugate (ADC) topoisomerase 1 inhibitor payload and cleavable linker, demonstrated promising preliminary results in pts relapsed/refractory (r/r) ES-SCLC (Spira et al, ENA 2024). Here, we report updated data additional follow-up (NCT06179069). Methods: This is two-part Phase I...
3112 Background: NTRK gene fusion is one of the most defined driving factors carcinogenesis, which occurs in various adult tumor types. Zurlectrectinib, a highly selective next-generation TRK tyrosine kinase inhibitor, previously demonstrated encouraging efficacy and manageable toxicity pts with NTRK+ tumors phase I/II clinical trial (NCT04685226). The pivotal II (NCT05745623) currently ongoing. Here we present integrated results from both trials. Methods: Pts locally advanced or metastatic...
Ultrasonication-assisted solution casting was used to prepare polyvinyl alcohol (PVA)/sodium carboxymethyl cellulose (CMC)/nano-ZnO/multilayer graphene nanoplatelet (xGnP) composite films; the performances (mechanical properties, water vapor permeability (WVP), biodegradability and antibacterial activity) of these films were investigated as a function ZnO NPs:xGnP mass ratio ultrasonication time. Intermolecular interactions among NPs, xGnP PVA/CMC matrix shown improve WVP, while X-ray...
A new asymmetrical diarylethene containing a 1H-imidazo [4,5-f][1,10] phenanthroline unit was synthesized. The compound showed typical photochromism and functioned as notable fluorescence switch upon alternating irradiation with ultraviolet (UV) visible light. Its closed-ring isomer could be used selective ‘naked-eye’ colorimetric sensor for Cu2+, accompanied by color change from blue to colorless. Furthermore, the found towards Ca2+, Mg2+, Sr2+ significant changes. On basis of this...
This single-arm, multicenter, phase 2 trial (NCT04106180) investigated the triple combination of sintilimab (anti-PD1 antibody), stereotactic body radiotherapy (SBRT) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in metastatic non-small cell lung cancer (NSCLC). With a median follow-up 32.1 months, 18 (36.7%, 90% CI 25.3%–49.5%) 49 evaluable patients had an objective response, meeting primary endpoint. Secondary endpoints included out-of-field (abscopal) response rate (ASR),...